EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeted antisense oligonucleotide therapy rescues PRPF31 expression in retinitis pigmentosa caused by a splicing mutation

Poulami Banik, Felix Zimmann, Prasoon K Thakur, Lubica Dudakova, Kateřina Večerková, Ondrej Kostov, Marvin H Caruthers, Michal Kolář, Inka Krejčířová, Marie Vajter, Petra Liskova, Tomáš Bárta und 1 weitere

Molecular Therapy · 2026-10 · 34 (10) · 6060-6073

DOI: 10.1016/j.ymthe.2026.05.033 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2026-10. Verfasst von Poulami Banik und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Genetics, Czech Academy of Sciences, CZ 142 00 Prague, Czech Republic. Hauptthemen laut MEDLINE: Retinitis Pigmentosa, Oligonucleotides, Antisense, Eye Proteins, Mutation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health of the Czech Republic, Czech Science Foundation, Charles University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pathogenic variants in splicing factors are the second most common cause of autosomal dominant retinitis pigmentosa, with mutations in PRPF31 being the most prevalent. Here, we characterize a novel intronic variant in PRPF31 (c.1074-11C>G) that creates a cryptic 3' splice site, resulting in an aberrantly spliced transcript predicted to encode a protein with an altered C terminus. However, the pathogenic protein is unstable and undetectable in patient-derived induced pluripotent stem cells (iPSCs). In addition, expression of the full-length PRPF31 protein was reduced in patient-derived retinal pigment epithelium (RPE). To correct the splicing defect, we designed a panel of antisense oligonucleotides (ASOs) targeting putative RNA-binding sites in exon 10 and intron 10 and identified a candidate that corrects PRPF31 splicing in a minigene reporter system as well as in patient-derived iPSCs and RPE. We further showed that ASO treatment enhances PRPF31 protein expression in patient-derived iPSC and RPE carrying the intronic mutation, supporting the potential of the ASO-based approach to restore PRPF31 expression in patients with the same or similar splicing defects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Retinitis PigmentosaOligonucleotides, AntisenseEye ProteinsMutationRNA SplicingHumansInduced Pluripotent Stem CellsRetinal Pigment EpitheliumIntronsExons

Stichwörter der Autor:innen

ASOsPRPF31 protein expressionRNA splicingRPEantisense oligonucleotidesdifferentiated retinal pigment epitheliumiPSCsinduced pluripotent stem cellsretinitis pigmentosatherapy

Substanzen

Oligonucleotides, AntisensePRPF31 protein, humanEye Proteins

Autor:innen und Institutionen

  • Institute of Molecular Genetics, Czech Academy of Sciences, CZ 142 00 Prague, Czech Republic.
  • Institute of Molecular Genetics, Czech Academy of Sciences, CZ 142 00 Prague, Czech Republic; Department of Ecology, Environment and Plant Sciences, Stockholm University, 106 91 Stockholm, Sweden.
  • Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, CZ 121 08 Prague, Czech Republic.
  • Institute of Molecular Genetics, Czech Academy of Sciences, CZ 142 00 Prague, Czech Republic; Department of Informatics and Chemistry, University of Chemistry and Technology, CZ 166 28 Prague, Czech Republic.
  • Department of Biochemistry, University of Colorado Boulder, Boulder, CO 80303, USA.
  • Department of Pediatric Ophthalmology, University Hospital Brno and Faculty of Medicine, Masaryk University, CZ 625 00 Brno, Czech Republic.

Förderung

  • Ministry of Health of the Czech Republic
  • Czech Science Foundation
  • Charles University
  • Ministry of Education Youth and Sports of the Czech Republic

Zitieren

APA

Banik, P., Zimmann, F., Thakur, P. K., Dudakova, L., Večerková, K., Kostov, O., Caruthers, M. H., Kolář, M., Krejčířová, I., Vajter, M., Liskova, P., Bárta, T., & Staněk, D. (2026). Targeted antisense oligonucleotide therapy rescues PRPF31 expression in retinitis pigmentosa caused by a splicing mutation. Molecular Therapy, 34(10), 6060-6073. https://doi.org/10.1016/j.ymthe.2026.05.033

Vancouver

Banik P, Zimmann F, Thakur PK, Dudakova L, Večerková K, Kostov O, et al. Targeted antisense oligonucleotide therapy rescues PRPF31 expression in retinitis pigmentosa caused by a splicing mutation. Molecular Therapy. 2026;34(10):6060-6073. doi:10.1016/j.ymthe.2026.05.033

BibTeX
@article{Banik2026,
  author = {Banik, Poulami and Zimmann, Felix and Thakur, Prasoon K and Dudakova, Lubica and Večerková, Kateřina and Kostov, Ondrej and Caruthers, Marvin H and Kolář, Michal and Krejčířová, Inka and Vajter, Marie and Liskova, Petra and Bárta, Tomáš and Staněk, David},
  title = {Targeted antisense oligonucleotide therapy rescues PRPF31 expression in retinitis pigmentosa caused by a splicing mutation},
  journal = {Molecular Therapy},
  year = {2026},
  volume = {34},
  number = {10},
  pages = {6060--6073},
  doi = {10.1016/j.ymthe.2026.05.033}
}
Kostenlos starten →